The University of Pittsburgh and University of Pittsburgh Cancer Institute propose to conduct a Specialized Program of Research Excellence (SPORE) in Skin Cancer. The overall goals of the University Pittsburgh Skin Cancer SPORE are to improve the detection and treatment of skin cancer. The SPORE program will consist of six translational research projects in skin cancer, four cores including an administrative core, a developmental research program and a career development program. The University of Pittsburgh Skin Cancer SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co- investigators in basic, applied and clinical science. It is also organ-specific in that its approach and all projects will test hypotheses about skin cancer biology, susceptibility, detection, or treatment. The long-term translational research projects that will serve as the basis for improving the outcome of patients diagnosed with skin cancer. The six main projects include: (1) Chemoprevention of Melanoma with Sulforaphane;(2) Multiple Antigen-Engineered DC Immunization and IFN? Boost for Metastatic Melanoma;(3) Polarized Dendritic Cells Guide Melanoma-Specific Responses;(4) Therapeutic Immune Targeting of EphA2 Expressed by Melanoma and Its Tumor-Associated Vasculature;(5) Delineating the DNA Repair pathways impacting alkylating agent efficacy in the treatment of Melanoma;(6) Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-regs depletion. The four research cores will interact closely to assist the main research projects, developmental research projects and the career development investigators in carrying out translational skin cancer research. The research cores are: Core A. Administrative Core;Core B. Tissue Core;Core C. Immunological Monitoring and Cellular Products Laboratory (IMCPL);Core D. Biostatics. The Administrative Core will solicit feedback from the Internal and External Scientific Advisory Boards and provide scientific, regulatory and fiscal oversight for the SPORE program. The Skin SPORE investigators will work together to synergistically achieve the goals of the program and will also interact with investigators from SPOREs at other institutions to improve the outcome of patients with skin cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-04
Application #
8129541
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Program Officer
Agarwal, Rajeev K
Project Start
2008-08-26
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$2,185,000
Indirect Cost
Name
University of Pittsburgh
Department
Dermatology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Mathers, A R; Carey, C D; Killeen, M E et al. (2017) Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. Allergy 72:656-664
Davar, Diwakar; Ding, Fei; Saul, Melissa et al. (2017) High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 5:74
Booth, Laurence; Roberts, Jane L; Sander, Cindy et al. (2017) The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget 8:16367-16386
Najjar, Yana G; Ding, Fei; Lin, Yan et al. (2017) Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med 15:39
Butterfield, Lisa H (2017) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol :
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2017) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol :
Ferris, Laura K; Saul, Melissa I; Lin, Yan et al. (2017) A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol 3:1112-1115
Scharping, Nicole E; Menk, Ashley V; Whetstone, Ryan D et al. (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res 5:9-16
Overacre-Delgoffe, Abigail E; Chikina, Maria; Dadey, Rebekah E et al. (2017) Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell 169:1130-1141.e11
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697

Showing the most recent 10 out of 191 publications